Mohamed Maged E, El-Shafae Azza M, Fikry Eman, Elbaramawi Samar S, Elbatreek Mahmoud H, Tawfeek Nora
Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa, Saudi Arabia.
Department of Pharmacognosy, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt.
Front Pharmacol. 2023 Dec 22;14:1322181. doi: 10.3389/fphar.2023.1322181. eCollection 2023.
Ulcerative colitis (UC) is an inflammatory bowel disease that is often resistant to current treatment options, leading to a need for alternative therapies. Herbal products have shown promise in managing various conditions, including UC. However, the potential of branchlets ethanolic extract (CGBRE) in treating UC has not been explored. This study aimed to analyze the chemical composition of CGBRE and evaluate its efficacy in UC treatment through and experiments. LC-ESI-MS/MS was used to identify 86 compounds in CGBRE, with 21 potential bioactive compounds determined through pharmacokinetic analysis. Network pharmacology analysis revealed 171 potential UC targets for the bioactive compounds, including EGFR, LRRK2, and HSP90 as top targets, which were found to bind to key CGBRE compounds through molecular docking. Molecular docking findings suggested that CGBRE may be effective in the prevention or treatment of ulcerative colitis mediated by these proteins, where key CGBRE compounds exhibited good binding affinities through formation of numerous interactions. studies in rats with acetic acid-induced UC demonstrated that oral administration of 300 mg/kg CGBRE for 6 days reduced UC symptoms and colonic expression of EGFR, LRRK2, and HSP90. These findings supported the therapeutic potential of CGBRE in UC and suggested the need for further preclinical and clinical investigation.
溃疡性结肠炎（UC）是一种炎症性肠病，通常对目前的治疗方案具有抗性，因此需要替代疗法。草药产品在管理包括UC在内的各种病症方面已显示出前景。然而，尚未探索过细枝乙醇提取物（CGBRE）在治疗UC方面的潜力。本研究旨在分析CGBRE的化学成分，并通过体内和体外实验评估其在UC治疗中的疗效。采用液相色谱-电喷雾串联质谱法（LC-ESI-MS/MS）鉴定出CGBRE中的86种化合物，通过药代动力学分析确定了21种潜在的生物活性化合物。网络药理学分析揭示了生物活性化合物的171个潜在UC靶点，包括表皮生长因子受体（EGFR）、富亮氨酸重复激酶2（LRRK2）和热休克蛋白90（HSP90）作为主要靶点，通过分子对接发现它们与关键的CGBRE化合物结合。分子对接结果表明，CGBRE可能对预防或治疗由这些蛋白质介导的溃疡性结肠炎有效，其中关键的CGBRE化合物通过形成大量相互作用表现出良好的结合亲和力。在醋酸诱导的UC大鼠中的体内研究表明，口服300mg/kg CGBRE 6天可减轻UC症状以及结肠中EGFR、LRRK2和HSP90的表达。这些发现支持了CGBRE在UC中的治疗潜力，并表明需要进一步的临床前和临床研究。
